Waldenström macroglobulinemia: biology, genetics, and therapy
Jonas Paludo,1,2 Stephen M Ansell,1 1Division of Hematology, 2Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA Abstract: Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity characterized by the presence of a lymphoplasmacytic lymphoma, a non-Hodgkin lympho...
Saved in:
Main Authors: | Paludo J, Ansell SM |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/91e020a8d5054da7b86d0f67cce9353a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
by: C. I. Edvard Smith, et al.
Published: (2021) -
Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile
by: Cardemil,Daniela, et al.
Published: (2019) -
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
by: Ujjani C, et al.
Published: (2020) -
Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission
by: Seegobin K, et al.
Published: (2021) -
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
by: Carrà G, et al.
Published: (2019)